Se connecter

Bibliographies thématiques / Levothyroxine (LT4)

Sommaire

Articles de revues
Thèses
Chapitres de livres
Rapports d'organisations

Littérature scientifique sur le sujet « Levothyroxine (LT4) »

Auteur : Grafiati

Publié le 7 juin 2025

Mis à jour le 2 août 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Levothyroxine (LT4) ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Levothyroxine (LT4)"

1

Dutt, Rohit, Kailash Chander Malik, Manoj Karwa, and Gaurav Kumar JAIN. "Development and Validation of UPLC-MS/MS Method for Rapid Simultaneous Determination of Levothyroxine and Liothyronine in Human Serum." Journal of Drug Delivery and Therapeutics 10, no. 3-s (2020): 176–81. http://dx.doi.org/10.22270/jddt.v10i3-s.4189.

Texte intégral

Résumé :

A simple ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) method was developed and fully validated to simultaneously determine levothyroxine (LT4) and liothyronine (LT3) in human serum. Sample preparation was done through protein precipitation with acetonitrile. HyPURITY C18 column was selected to achieve rapid separation for LT4 and LT3 within 4 min. Electrospray ionization (ESI) under multiple reaction monitoring (MRM) was used to monitor the ion transitions for LT4 (m/z 777.54→731.52), LT3 (m/z 651.64→ 605.65) and internal standard LT4-D3 (m/z

Styles APA, Harvard, Vancouver, ISO, etc.

2

Vishnumaya, A. M. Anjali Krishna S. S. Alnon L. J*. Shaiju S. Dharan. "Assessment of Quality of Life Among Patients with Hypothyroidism on Levothyroxine: A Review." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 830–40. https://doi.org/10.5281/zenodo.15345188.

Texte intégral

Résumé :

Hypothyroidism is the most common endocrine disorders that significantly impacts patient health related quality of life (HRQoL). Levothyroxine (LT4) is the primary treatment used alone to restore normal thyroid hormone levels. This review examines how levothyroxine (LT4) treatment influences the quality of life in individuals diagnosed with hypothyroidism. It assesses the effectivity of levothyroxine in symptom resolution, explore factors influencing QoL, and identify possible shortcomings in the current treatment plan. This review evaluates recent observational studies and meta-analyses that

Styles APA, Harvard, Vancouver, ISO, etc.

3

Bjerkreim, Betty Ann, Sara Salehi Hammerstad, Hanne Løvdal Gulseth, Tore Julsrud Berg, Sindre Lee-Ødegård, and Erik Fink Eriksen. "Thyroid Signaling Biomarkers in Female Symptomatic Hypothyroid Patients on Liothyronine versus Levothyroxine Monotherapy: A Randomized Crossover Trial." Journal of Thyroid Research 2022 (May 4, 2022): 1–10. http://dx.doi.org/10.1155/2022/6423023.

Texte intégral

Résumé :

Background. Levels of thyroid-stimulating hormone (TSH) are believed to reflect degree of disease in patients with hypothyroidism, and normalization of levels is the treatment goal. However, despite adequate levels of TSH after starting levothyroxine (LT4) therapy, 5–10% of hypothyroid patients complain of persisting symptoms with a significant negative impact on quality of life. This indicates that TSH is not an optimal indicator of intracellular thyroid hormone effects in all patients. Our aim was to investigate different effects of LT3 and LT4 monotherapy on other biomarkers of the thyroid

Styles APA, Harvard, Vancouver, ISO, etc.

4

Meizlik, Paige, Andrew Cucchiara, Lakshmi Kannan, et al. "Physiologic Effects of Levothyroxine and Liothyronine in the in Older Individuals With Persistent Subclinical Hypothyroidism: A Randomized, Double-Blind, Cross-Over Study." Journal of the Endocrine Society 5, Supplement_1 (2021): A976—A977. http://dx.doi.org/10.1210/jendso/bvab048.1996.

Texte intégral

Résumé :

Abstract Background: Subclinical hypothyroidism is common in older individuals, but the physiologic responses to treatment with levothyroxine (LT4) and liothyronine (LT3) are not well defined in this age group. Methods: We conducted a randomized, double-blind, cross-over study of LT4 and LT3 treatment in men and women aged 70 years and over without anti-thyroid peroxidase antibodies with persistent subclinical hypothyroidism, defined as having a TSH level between 4.5 and 19.9 µIU/mL with a normal free thyroxine (FT4) level at two consecutive time points. Physiologic outcome measures assessed a

Styles APA, Harvard, Vancouver, ISO, etc.

5

Solter, D., and M. Solter. "Benefit of Combined Triiodothyronine (LT3) and Thyroxine (LT4) Treatment in Athyreotic Patients Unresponsive to LT4 Alone." Experimental and Clinical Endocrinology & Diabetes 120, no. 02 (2011): 121–23. http://dx.doi.org/10.1055/s-0031-1297253.

Texte intégral

Résumé :

AbstractDespite some reports, the usefulness of levothyroxine ( LT4) and levotriiodothyronine (LT3) combination therapy in hypothyroidism remains controversial. The objective of this paper is to study a benefit of additional LT3 in athyreotic patients who failed to normalize TSH on LT4 alone even with hyperthyroid serum T4 values.In a survey of 200 athyreotic patients treated between 2006 and 2009, about 7% failed to normalize serum TSH levels following treatment with LT4, though serum T4 values in the hyperthyroid range were achieved. These patients (characterized by serum T4≥160 nmol/L and T

Styles APA, Harvard, Vancouver, ISO, etc.

6

Shepelkevich, A. P., Yu V. Dydyshka, E. V. Yurenya та ін. "Features of the use of synthetic analogues of thyroid hormones: а 2020 THESIS* questionnaire survey of members of the Belarusian Public Medical Association of Endocrinology and Metabolism". Problems of Endocrinology 68, № 1 (2021): 18–26. http://dx.doi.org/10.14341/probl12828.

Texte intégral

Résumé :

BACKGROUND. The standard treatment for hypothyroidism is levothyroxine (LT4), which in the Republic of Belarus is available in tablet form whereas liothyronine (LT3) is not registered, but patients can purchase them on their own abroad.AIM. This study aimed to investigate Belarusian endocrinologists’ attitude of thyroid hormones in hypothyroid and euthyroid patients.MATERIALS AND METHODS. An online survey was conducted, for which members of the Belarusian Medical Association of Endocrinology and Metabolism were invited by posting information in the group chat and by e-mail. The research period

Styles APA, Harvard, Vancouver, ISO, etc.

7

Razvi, Salman, Sanaa Mrabeti, and Markus Luster. "Managing symptoms in hypothyroid patients on adequate levothyroxine: a narrative review." Endocrine Connections 9, no. 11 (2020): R241—R250. http://dx.doi.org/10.1530/ec-20-0205.

Texte intégral

Résumé :

The current standard of care for hypothyroidism is levothyroxine (LT4) monotherapy to reduce levels of thyrotropin (thyroid-stimulating hormone, TSH) within its reference range and amelioration of any symptoms. A substantial minority continues to report hypothyroid-like symptoms despite optimized TSH, however. These symptoms are not specific to thyroid dysfunction and are frequent among the euthyroid population, creating a therapeutic dilemma for the treating clinician as well as the patient. We present a concise, narrative review of the clinical research and evidence-based guidance on the man

Styles APA, Harvard, Vancouver, ISO, etc.

8

Meizlik, Paige, Andrew Cucchiara, Lakshmi Kannan, Theresa Scattergood, and Anne Rentoumis Cappola. "TRH Stimulation Testing in Older Individuals with Persistent Subclinical Hypothyroidism: A Randomized, Double-Blind, Cross-Over Study of Levothyroxine and Liothyronine Administration." Journal of the Endocrine Society 5, Supplement_1 (2021): A853—A854. http://dx.doi.org/10.1210/jendso/bvab048.1742.

Texte intégral

Résumé :

Abstract Background: Subclinical hypothyroidism is common in older individuals. To better understand the underlying physiology, we examined the pituitary-thyroid axis using thyrotropin releasing hormone (TRH) stimulation testing both at baseline and after levothyroxine (LT4) and liothyronine (LT3) supplementation. Methods: We conducted a randomized, double-blind, cross-over study in men and women aged 70 years and over without anti-thyroid peroxidase antibodies with persistent subclinical hypothyroidism, defined as having a TSH level between 4.5 and 19.9 µIU/mL with a normal free thyroxine (FT

Styles APA, Harvard, Vancouver, ISO, etc.

9

Ettleson, Matthew D., and Antonio C. Bianco. "Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?" Journal of Clinical Endocrinology & Metabolism 105, no. 9 (2020): e3090-e3104. http://dx.doi.org/10.1210/clinem/dgaa430.

Texte intégral

Résumé :

Abstract Context It is well recognized that some hypothyroid patients on levothyroxine (LT4) remain symptomatic, but why patients are susceptible to this condition, why symptoms persist, and what is the role of combination therapy with LT4 and liothyronine (LT3), are questions that remain unclear. Here we explore evidence of abnormal thyroid hormone (TH) metabolism in LT4-treated patients, and offer a rationale for why some patients perceive LT4 therapy as a failure. Evidence Acquisition This review is based on a collection of primary and review literature gathered from a PubMed search of “hyp

Styles APA, Harvard, Vancouver, ISO, etc.

10

Vargas-Uricoechea, Hernando, and Leonard Wartofsky. "LT4/LT3 Combination Therapy vs. Monotherapy with LT4 for Persistent Symptoms of Hypothyroidism: A Systematic Review." International Journal of Molecular Sciences 25, no. 17 (2024): 9218. http://dx.doi.org/10.3390/ijms25179218.

Texte intégral

Résumé :

Regardless of the cause, hypothyroidism should be treated with levothyroxine. The objectives of management are the normalization of TSH levels and the relief of symptoms. In general, the vast majority of patients who achieve normalization of TSH levels show a resolution of symptoms; however, for a small number of individuals, symptoms persist (despite adequate control of TSH). This scenario generates a dilemma in the therapeutic approach to these patients, because even when excluding other causes or concomitant diseases that can explain the persistence of symptoms, pharmacological management s

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Levothyroxine (LT4)"

1

Hibelot, Catherine. "Etude comparative de deux traitements substitutifs de l'hypothyroidie LT3 et LT4 : répercussions osseuses au bout de un an." Bordeaux 2, 1992. http://www.theses.fr/1992BOR2M032.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Levothyroxine (LT4)"

1

Gunasekaran, Kalaipriya, and Ngiap Chuan Tan. "Optimizing Levothyroxine replacement in primary care practice." In Hypothyroidism - Causes, Screening and Therapeutic Approaches [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.1005906.

Texte intégral

Résumé :

Individuals with hypothyroidism will require lifelong thyroxine replacement therapy to alleviate symptoms and prevent long-term consequences. Levothyroxine (LT4), a synthetic form of thyroxine (T4), is the standard and most prescribed medication for managing hypothyroidism. Triiodothyronine (T3) is another thyroid hormone that can be used in replacement therapy, but it is not typically used as a first-line treatment. However, a combination of T4 and T3 may be considered in uncommon situations when T4 to T3 conversions are reduced. Optimal replacement therapy is individualized, and factors such

Styles APA, Harvard, Vancouver, ISO, etc.

2

Abassi, Wissal, Nejmeddine Ouerghi, and Anissa Bouassida. "Hypothyroidism Therapy." In Hypothyroidism - New Aspects of an Old Disease. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.99978.

Texte intégral

Résumé :

Hypothyroidism refers to the common pathological disorder of thyroid hormone deficiency. The successful therapy for hypothyroidism is levothyroxine (LT4) administration, which is the same as thyroxine but produced synthetically. Serum thyrotropin (TSH) normalization with LT4 replacement therapy in hypothyroidism is generally needed to restore a euthyroid state. The daily dose of thyroxine therapy depends on various factors, such as body weight, age, and severity. It also differs from hypothyroidism during pregnancy to congenital hypothyroidism. The presence of various comorbidities may exist s

Styles APA, Harvard, Vancouver, ISO, etc.

3

Benvenga, Salvatore, and Murray P. Ducharme. "Comparison of the Intestinal Absorption of Levothyroxine (LT4): Tabletvs.Soft Gel Capsule Formulation." In The Endocrine Society's 93rd Annual Meeting & Expo, June 4–7, 2011 - Boston. The Endocrine Society, 2011. http://dx.doi.org/10.1210/endo-meetings.2011.part4.p9.p3-625.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Schauer, Irene. "Case 18: A Common Misdiagnosis." In Diabetes Case Studies: Real Problems, Practical Solutions. American Diabetes Association, 2015. http://dx.doi.org/10.2337/9781580405713.18.

Texte intégral

Résumé :

M. is a 59-year-old Caucasian man referred to an endocrinology clinic for assistance with levothyroxine dosing for his hypothyroidism post I-131 ablation for Graves’ disease about 8 years earlier. He had been noting increasing fatigue and weight loss that he associated with his thyroid medication and requested endocrinology consultation. His primary provider had decreased his LT4 dose by 15% 1 month prior to his endocrine visit in response to a reported thyroid-stimulating hormone (TSH) of 0.25 μIU/mL. The patient had noted no improvement in his symptoms with this change. His past medical hist

Styles APA, Harvard, Vancouver, ISO, etc.

5

Vaidya, Bijay, and Chantal Daumerie. "Subclinical Hypothyroidism." In Oxford Textbook of Endocrinology and Diabetes 3e, edited by John A. H. Wass, Wiebke Arlt, and Robert K. Semple. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0070.

Texte intégral

Résumé :

Subclinical hypothyroidism is a common condition associated with a raised serum thyroid-stimulating hormone (TSH) but normal serum free thyroxine and triiodothyronine. It is more prevalent in women and people with advancing age. Most patients with subclinical hypothyroidism are asymptomatic. About 2.5% patients progress to overt hypothyroidism annually although the rate of progression is higher in the presence of thyroid autoantibodies. Subclinical hypothyroidism is associated with an increased risk of coronary heart disease, heart failure and cerebrovascular disease in younger patients (<6

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Levothyroxine (LT4)"

1

Liu, Gejing, Man Ren, Yingshi Du, et al. A meta-analysis of Effect of thyroid hormone replacement therapy on the Cardiac diastolic function in Patients with Subclinical Hypothyroidism. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.2.0083.

Texte intégral

Résumé :

Review question / Objective: P:Subclinical Hypothyroidism(Age over 18); I:thyroid hormone replacement therapy; C:baseline(before-after study in the same patient); O:Cardiac diastolic function measurement by echocardiography. Condition being studied: Subclinical hypothyroidism is associated with anomalies left ventricular diastolic functions, however, there are still disputes about whether to use levothyroxine for treatment. This meta-analysis aimed to determine whether levothyroxine (LT4), commonly used to treat hypothyroidism, affects cardiovascular indices in SCH patients as measured by echo

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!